INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies.

Autor: van Haren FMP; Australian National University, College of Health and Medicine, Canberra, Australia.; Faculty of Health, University of Canberra, Canberra, Australia., Richardson A; Statistical Consulting Unit, Australian National University, Canberra, Australia., Yoon HJ; Statistical Consulting Unit, Australian National University, Canberra, Australia., Artigas A; Critical Center, Corporació Universitaria Sanitaria Parc Tauli, CIBER Enfermedades Respiratorias, Autonomous University of Barcelona, Sabadell, Spain., Laffey JG; Anaesthesia and Intensive Care Medicine, School of Medicine, and Regenerative Medicine Institute (REMEDI) at CÚRAM Centre for Research in Medical Devices, Biomedical Sciences Building, National University of Ireland Galway, Galway, Ireland.; Department of Anaesthesia, University Hospital Galway, Saolta Hospital Group, Ireland., Dixon B; Department of Critical Care Medicine, St Vincent's Hospital, Melbourne, Australia., Smith R; Department of Critical Care Medicine, St Vincent's Hospital, Melbourne, Australia., Vilaseca AB; Service of Haematology and Haemostasis, San Camilo Clinic, Buenos Aires, Argentina., Barbera RA; Service of Haematology and Haemostasis, San Camilo Clinic, Buenos Aires, Argentina., Ismail TI; Department of Anaesthesia and Surgical Intensive Care, Faculty of Medicine, Helwan University, Cairo, Egypt., Mahrous RS; Department of Anaesthesia and Surgical Intensive Care, Faculty of Medicine, Alexandria University, Alexandria, Egypt., Badr M; Department of Critical Care Medicine, Faculty of Medicine, Helwan University, Cairo, Egypt., De Nucci G; Department of Pharmacology, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil.; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, Brazil., Sverdloff C; Department of Pharmacology, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil., van Loon LM; Australian National University, College of Health and Medicine, Canberra, Australia., Camprubi-Rimblas M; Critical Center, Corporació Universitaria Sanitaria Parc Tauli, CIBER Enfermedades Respiratorias, Autonomous University of Barcelona, Sabadell, Spain., Cosgrave DW; Department of Anaesthesia, University Hospital Galway, Saolta Hospital Group, Ireland., Smoot TL; Frederick Memorial Hospital, Frederick, Maryland, USA., Staas S; Frederick Memorial Hospital, Frederick, Maryland, USA., Sann K; Frederick Memorial Hospital, Frederick, Maryland, USA., Sas C; Frederick Memorial Hospital, Frederick, Maryland, USA., Belani A; Frederick Memorial Hospital, Frederick, Maryland, USA., Hillman C; Frederick Memorial Hospital, Frederick, Maryland, USA., Shute J; School of Pharmacy and Biomedical Science, University of Portsmouth, Portsmouth, UK., Carroll M; Department of Respiratory Medicine, University of Southampton, Southampton, UK., Wilkinson T; Department of Respiratory Medicine, University of Southampton, Southampton, UK., Carroll M; National Infection Service, Public Health England, Porton Down, UK., Singh D; Medicines Evaluation Unit, University of Manchester, Manchester, UK., Page C; Sackler Institute of Pulmonary Pharmacology, King's College London, UK.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2021 Aug; Vol. 87 (8), pp. 3075-3091. Date of Electronic Publication: 2021 Jan 19.